Ysios Capital

2Exits tracked$1.95bnDisclosed value$1.15bnMedian price0Acquihires

Startups backed by Ysios Capital that were acquired: 2 exits so far, with the buyer, the price where disclosed and every source.

Photo: Rhoda Baer (Photographer) / Wikimedia Commons, Public domain

Healthtech & bio · Schlieren

Ipsen to buy Swiss biotech Memo Therapeutics for €200 million upfront plus milestones

The French drugmaker is paying for one asset: potravitug, a Phase II antibody against BK polyomavirus in kidney-transplant patients. Memo's discovery platform and other staff are being split off into a new company its shareholders keep.

Price$800mRaisedn/aLast stageSeries CBuyer typeCorporate

Latest in Ysios CapitalSouth San Francisco · Healthtech & bioUCB to acquire epilepsy cell therapy developer Neurona Therapeutics for up to $1.15 billion$1bn+Series D+17 Apr

All Ysios Capital exitsOpen tracker →

1 JulIpsen → Memo TherapeuticsSchlieren · Series C · raised n/a$800m$250m–1bn 17 AprUCB → Neurona TherapeuticsSouth San Francisco · Series D+ · raised $318m$1.15bn$1bn+